The roles of METTL3 on autophagy and proliferation of vascular smooth muscle cells are mediated by mTOR rather than by CDK1

Hanshen Luo, Xingliang Wu, Bo Huo, Liyuan Liu, Ding‐Sheng Jiang, Xin YiCell Division 2023 · DOI

TL;DR

This study investigates how METTL3, a key RNA-modifying enzyme, influences vascular smooth muscle cell (VSMC) proliferation and autophagy. The researchers found that METTL3's effects on proliferation and autophagy are primarily mediated by the mTOR pathway, not CDK1, offering new insights into the mechanisms behind vascular diseases like neointima formation.

What Problem Does This Paper Address?

Vascular smooth muscle cells (VSMCs) play a critical role in maintaining blood vessel structure. However, their aberrant proliferation is a major contributor to neointima formation, a process that underlies many vascular diseases, including atherosclerosis and restenosis after angioplasty. Autophagy, a cellular self-degradation process, has been implicated in VSMC proliferation and survival, but its precise role is still debated. Previous work by the authors showed that METTL3, an enzyme that modifies RNA, inhibits VSMC proliferation by promoting autophagosome formation and reducing levels of phosphorylated mTOR (p-mTOR) and CDK1 (p-CDK1). However, it remained unclear whether mTOR and CDK1 were the actual mediators of METTL3's actions on VSMC proliferation and autophagy. This paper aims to elucidate the specific roles of mTOR and CDK1 in mediating METTL3's functions in VSMCs.

Methods

The researchers employed a combination of molecular biology techniques to investigate the roles of METTL3, mTOR, and CDK1 in VSMCs. Key methods included:

  • Overexpression and Knockdown: Lentiviral vectors were used to overexpress METTL3 or to knock down (reduce the expression of) METTL3 and CDK1 in primary human aortic smooth muscle cells (HASMCs).
  • Western Blotting: This technique was used to detect and quantify the protein levels of METTL3, mTOR, p-mTOR, CDK1, p-CDK1, and autophagy-related proteins (ATG5, ATG7, LC3II), as well as proliferation markers (PCNA, p-H3).
  • Pharmacological Treatments: The mTOR activator MHY1485 and the mTOR inhibitor rapamycin were used to manipulate mTOR signaling pathways.
  • Transwell Assay: This assay was used to assess the migratory capacity of HASMCs.
  • Real-time PCR: Used to measure mRNA levels of key genes.

Datasets

Not discussed in the paper. The study primarily uses cell culture models (HASMCs) and experimental manipulations rather than large-scale datasets.

Key Insights and Ideas

  • mTOR is the Key Mediator: The most significant finding is that mTOR, but not CDK1, acts as the primary downstream effector of METTL3's influence on VSMC proliferation and autophagy. This clarifies a crucial signaling axis.
  • Autophagy is Central to METTL3's Proliferation Control: The study reinforces the idea that METTL3's inhibition of VSMC proliferation is tightly linked to its ability to promote autophagy. When mTOR is activated, it reverses METTL3's effects on autophagy and proliferation, highlighting the dependence of these processes on mTOR activity.
  • CDK1's Role is Separate from Autophagy: While CDK1 knockdown did affect METTL3-regulated proliferation, it did not impact autophagy. This suggests CDK1 might play a role in cell cycle progression independent of the autophagy pathway in this context.
  • METTL3's Effects on Migration and Phenotype are mTOR-Independent: Interestingly, mTOR manipulation did not alter METTL3's impact on VSMC migration or phenotypic switching, suggesting these functions are regulated by different pathways.

Key Results

  • mTOR Activation Reverses METTL3 Effects: Treatment with the mTOR activator MHY1485 largely reversed the inhibitory effects of METTL3 overexpression on VSMC autophagy and proliferation.
  • mTOR Inhibition Rescues METTL3 Knockdown Effects: Conversely, inhibiting mTOR with rapamycin nullified the pro-proliferation effects seen when METTL3 was knocked down, while simultaneously promoting autophagy.
  • CDK1 Knockdown Affects Proliferation but Not Autophagy: Knocking down CDK1 in VSMCs with METTL3 deficiency significantly reduced the pro-proliferative effects of METTL3 knockdown. However, CDK1 knockdown did not counteract METTL3's effects on autophagy.
  • mTOR Does Not Mediate Migration/Phenotype Changes: Neither activating nor inhibiting mTOR affected METTL3's influence on VSMC migration or phenotypic switching.

Limitations and Future Work

  • In Vitro Study: The study was conducted using cultured HASMCs. While these cells are a standard model, future research should validate these findings in in vivo models of vascular injury and disease to confirm their relevance in a more complex biological setting.
  • Specific Pathways: While the study identifies mTOR as the key mediator, the precise downstream targets and mechanisms by which mTOR influences METTL3-mediated autophagy and proliferation require further investigation.
  • CDK1's Independent Role: The exact mechanism by which CDK1 influences METTL3-regulated proliferation, independent of autophagy, remains to be fully elucidated.
  • Clinical Translation: The authors suggest that these findings provide novel targets for the prevention and treatment of neointima formation. Future work could explore therapeutic strategies targeting the METTL3-mTOR axis for vascular diseases.

Summary updated

Abstract

BACKGROUND: Aberrant proliferation of vascular smooth muscle cells (VSMCs) is the cause of neointima formation followed by vascular injury. Autophagy is involved in this pathological process, but its function is controversial. Recently, we found that methyltransferase like 3 (METTL3) inhibited VSMC proliferation by activating autophagosome formation. Moreover, we also demonstrated that METTL3 reduced the levels of phosphorylated mammalian target of rapamycin (p-mTOR) and cyclin dependent kinase 1 (p-CDK1/CDC2), which were critical for autophagy and proliferation regulation. However, whether mTOR and CDK1 mediated the function of METTL3 on autophagy and proliferation in VSMCs remains unknown. RESULTS: We showed that the activator of mTOR, MHY1485 largely reversed the effects of METTL3 overexpression on VSMC autophagy and proliferation. Rapamycin, the inhibitor of mTOR, obviously nullified the pro-proliferation effects of METTL3 knockdown by activating autophagy in VSMCs. Unexpectedly, mTOR did not contribute to the impacts of METTL3 on migration and phenotypic switching of VSMCs. On the other hand, by knockdown of CDK1 in VSMC with METTL3 deficiency, we demonstrated that CDK1 was involved in METTL3-regulated proliferation of VSMCs, but this effect was not mediated by autophagy. CONCLUSIONS: We concluded that mTOR but not CDK1 mediated the role of METTL3 on VSMC proliferation and autophagy.
BibTeX
@inproceedings{luo2023roles,
  author = {Hanshen Luo and Xingliang Wu and Bo Huo and Liyuan Liu and Ding‐Sheng Jiang and Xin Yi},
  title = {{The roles of METTL3 on autophagy and proliferation of vascular smooth muscle cells are mediated by mTOR rather than by CDK1}},
  booktitle = {Cell Division},
  year = {2023},
  doi = {10.1186/s13008-023-00096-5},
}
Figure